Brought to you by 
Innovex to co-promote CV Therapeutics' angina drug
25 Apr 2000
Executive Summary
In the US, Quintiles Transnational Corp's Innovex contract sales division will market and sell CV Therapeutics' Phase III angina therapeutic ranolazine. Innovex bought (uf)$5mm of CVT common stock, will make a $10mm milestone payment when the drug is FDA approved, and offer a $10mm line of credit, which it could convert into CVT common stock at its option.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Innovex to co-promote CV Therapeutics' angina drug
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice